Allergan Rejects Valeant's $45.7B Takeover Bid
International Business Times
Published May 13, 2014 03:39AM ET
Updated May 13, 2014 04:00AM ET
Allergan Rejects Valeant's $45.7B Takeover Bid
By Sneha Shankar - Allergan Inc's (NYSE:AGN) board Monday rejected an unsolicited takeover proposal by Valeant Pharmaceuticals (TO:VRX) worth $45.7 billion, stating that the deal undervalued the Botox-maker.
Allergan said in a statement Tuesday that Canada-based Valeant’s proposal not only undervalued the Irvine, Calif.-based company, but also created significant risks and uncertainties for the company and its stockholders. Valeant had offered to acquire Allergan on April 22 for $48.30 a share in cash and a stock swap of 0.83 of its common share for each Allergan share, which added up to a valuation of $152.88 a share, which was at a premium of over 7 percent to Allergan’s stock price at the time.
“After careful review and consideration, our Board of Directors has unanimously determined that Valeant's unsolicited proposal substantially undervalues Allergan and does not reflect the value of the Company's leading market positions, sales and marketing foundation, industry-leading research and development efforts, as well as future revenue and earnings growth," David E.I. Pyott, Allergan's chairman and CEO, said in the statement.
Pyott also wrote a letter to Valeant’s Chairman and CEO Michael Pearson, according to the statement, where he asked for more clarity on Valeant's plans to cut costs “without harming the long term viability and growth trajectory of our business,” adding that the strategy that Valeant follows counters Allergan’s approach.
“We are disappointed that Allergan has rejected our value-creating offer without engaging in any substantive discussions with Valeant or Allergan's largest stockholder, Pershing Square, and we remain committed to pursuing this transaction,” Laurie Little, Valeant’s spokesperson, said according to Fox News.
The bid was handled by New York-based Pershing Square Capital Management, which is headed by William Ackman.
“We believe Allergan is in a great spot,” David Maris, an industry analyst at BMO Capital Markets Corp. in New York, said in a note, according to Bloomberg, adding: "Valeant’s prospects of completing this deal are less than 50 percent.’’
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.